• 5 min read
• Published on 10 February 2026
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article
Is Big Pharma’s Punt on Genetic Medicine a Smart Bet?
Let’s be honest, when a pharmaceutical giant like Eli Lilly drops a cool $2.4 billion on a small biotech firm, you tend to sit up and take notice. Their acquisition of Orna Therapeutics isn't just a headline, it’s a thunderous signal that the game is changing. For years, we’ve heard whispers about genetic medicine. Now, it seems the industry’s old guard has finally admitted they can’t build this new world themselves, so they’re buying it instead. To me, this suggests a genuine shift, not just another round of corporate speculation.
So, what is all the fuss about? Traditional medicine, frankly, is a bit of a plaster. It covers up symptoms. Genetic medicine, on the other hand, aims to rewrite the faulty code causing the problem in the first place. Think of it less like taking a painkiller for a headache and more like fixing the faulty wiring that causes it. Orna’s special trick is something called circular RNA. Unlike its fragile, linear cousins, this stuff is built to last, potentially turning daily pills into occasional, long lasting treatments. Now, does that sound like a revolution to you?
For an investor, this isn't just one big bet. I see it as three distinct opportunities. First, you have the gene editing tools themselves, like CRISPR. These are the molecular scissors, the fundamental technology. Then you have the therapies, the actual RNA molecules doing the work, which is where companies like Moderna are focusing after their vaccine success. Finally, and perhaps most crucially, you have the delivery systems. It’s no good having a magic bullet if you can't get it to the target. These systems are the picks and shovels of the genetic gold rush, essential for almost everyone in the field.
Before you get carried away, a word of caution. This is the wild frontier of medicine. The path from a brilliant idea to an approved treatment is long, brutally expensive, and littered with failures. For every success story, countless companies will simply run out of cash and disappear. The risks are enormous. If you're still curious about this new frontier, and I don't blame you, understanding the landscape is paramount. The Investment Opportunities in RNA Therapeutics Explained basket might offer a map of the territory, but remember, there could well be dragons. Invest accordingly.
View the full Basket:Investment Opportunities in RNA Therapeutics Explained
View the full Basket:Investment Opportunities in RNA Therapeutics Explained
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article